Immunosuppression with mTOR inhibitors prevents the development of donor‐specific antibodies after liver transplant

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Transplantation

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ctr.12974PMID 28345271
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation

  2015cited by this paper
• De novo donor‐specific anti‐HLA antibodies mediated rejection in liver‐transplant patients

  2015cited by this paper
• Prevalence, Incidence and Risk Factors for Donor‐Specific Anti‐HLA Antibodies in Maintenance Liver Transplant Patients

  2014cited by this paper
• Antibody‐mediated rejection as a contributor to previously unexplained early liver allograft loss

  2014cited by this paper
• Presence of Antibodies against Self Human Leukocyte Antigen Class II Molecules in Autoimmune Hepatitis

  2014cited by this paper
• Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors.

  2014cited by this paper
• Evolution of donor‐specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors

  2014cited by this paper
• Donor-specific antibodies in allograft recipients: etiology, impact and therapeutic approaches

  2014cited by this paper
• De Novo Donor‐Specific HLA Antibodies Decrease Patient and Graft Survival in Liver Transplant Recipients

  2013influential reference
• Early Versus Late Acute Antibody-Mediated Rejection in Renal Transplant Recipients

  2013cited by this paper
• Donor‐Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation

  2012cited by this paper
• Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody‐Mediated Rejection and Nonadherence

  2012cited by this paper
• Prevalence, Course and Impact of HLA Donor‐Specific Antibodies in Liver Transplantation in the First Year

  2012cited by this paper
• The Significance of Donor‐Specific HLA Antibodies in Rejection and Ductopenia Development in ABO Compatible Liver Transplantation

  2011cited by this paper
• Liver allograft antibody‐mediated rejection with demonstration of sinusoidal C4d staining and circulating donor‐specific antibodies

  2011cited by this paper
• Understanding the Causes of Kidney Transplant Failure : The Dominant Role of Antibody-Mediated Rejection and Nonadherence

  2011cited by this paper
• Liver transplantation in autoimmune liver diseases.

  2011cited by this paper
• Long‐term outcome of human leukocyte antigen mismatching in liver transplantation: Results of the national institute of diabetes and digestive and kidney diseases liver transplantation database

  2008cited by this paper
• Effects of cyclosporine, tacrolimus and sirolimus on vascular changes related to immune response.

  2008cited by this paper
• Cellular and molecular mechanisms of liver tolerance

  2006cited by this paper
• An Appraisal of Tolerance in Liver Transplantation

  2006cited by this paper
• The lifestyle of naturally occurring CD4+CD25+Foxp3+ regulatory T cells

  2006cited by this paper
• C4d in Liver Allografts: A Sign of Antibody‐Mediated Rejection?

  2006cited by this paper
• CONSORT statement: extension to cluster randomised trials

  2004cited by this paper
• CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production

  1998cited by this paper
• Combined liver-kidney transplantation: long-term follow up in 18 patients

  1998cited by this paper
• Cytomegalovirus infection induces anti-endothelial cell antibodies in cardiac and renal allograft recipients.

  1997cited by this paper
• Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1‐B8‐DR3 are independent risk factors

  1991cited by this paper
• Practical statistics for medical research

  1990cited by this paper
• Fully allogeneic liver grafting in rats induces a state of systemic nonreactivity to donor transplantation antigens.

  1980cited by this paper

• Impact of very early introduction of everolimus on liver regeneration after partial liver transplantation in rats

  2023cites this paper
• Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies

  2021cites this paper
• HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level

  2020cites this paper
• Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies

  2020cites this paper
• Long-term outcomes and clinical impact of anti-HLA donor-specific antibodies (DSA) after liver transplantation: prospective study in a pilot cohort.

  2020cites this paper
• Targeting the mTOR regulatory network in hepatocellular carcinoma: Are we making headway?

  2019cites this paper
• Prevalence and Impact of Reformed and De Novo Anti-HLA Donor-Specific Antibodies in Liver Transplantation.

  2019cites this paper
• The Effect of Immunosuppression on Coagulation After Liver Transplantation

  2019cites this paper
• Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation.

  2019cites this paper
• Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients.

  2018cites this paper